Medical - Baros Surgery

Treatment Overview

Treatment Type: Non-Surgical / Medical
Program Duration: 3–12+ Months
Weight Loss: 5–20% Total Body Weight
Approach: Lifestyle + OMM + Endoscopic

Medical Weight Management

Non-Surgical Solutions for Lasting Weight Loss

Not every patient requires surgery. Medical weight management offers a comprehensive, evidence-based pathway combining lifestyle modification, FDA-approved obesity management medications, and endoscopic procedures — achieving meaningful weight loss without a single surgical incision.

At Baros Apollo, the medical program is supervised by the same bariatric team that performs surgery, ensuring clinical rigor at every stage. Whether as standalone treatment or a bridge to surgical intervention, this approach delivers 5–20% total body weight loss with proper adherence.

First-Line Treatment

Lifestyle Management — The Foundation

First-line weight loss programs focus on lifestyle modifications including balanced diet, regular exercise, proper sleep, stress management, and behavioral changes. Most patients realistically achieve and sustain 5–10% total weight loss over the long term through these changes alone.

Diet & Exercise Planning

Calorie control, portion management, and 150+ minutes weekly strength and cardio training.

Behavioral Counseling

Sleep hygiene, stress management, and habit modification under expert guidance.

Patient Adherence Success Rate

85%

5–10% total weight loss sustained with lifestyle changes alone
Foundation for all other weight management therapies

Book a Consultation

FDA-Approved Treatments

Obesity Management Medications

Semaglutide Injection

Ozempic and Wegovy contain semaglutide, a once-weekly GLP-1 agonist. Doses from 0.5 to 2.4 mg. Delivers 10–13% total weight loss with significant cardiovascular benefits and improved metabolic control.

Tirzepatide (Mounjaro)

Dual GIP & GLP-1 receptor agonist. Once-weekly injection, 2.5–15 mg. Achieves 12–16% total weight loss with significant visceral fat reduction. Combining with EndoBariatrics may push total loss up to 20%.

Semaglutide Tablets (Rybelsus)

Oral daily GLP-1 agonist taken before food. Available in 3, 7, and 14 mg doses. Supports 7–10% weight loss and improves metabolic and cardiovascular health without injections.

Non-Surgical Procedures

Endoscopic Bariatrics

Procedures Performed Through the Mouth

Endoscopic Sleeve Gastroplasty

Stomach reduced via endoscopic suturing under anesthesia. Day care or overnight stay. Up to 20% total weight loss with OMM and healthy lifestyle.

Intragastric Balloon

Soft silicone balloon placed in stomach with 500–750 cc saline fill. Creates early fullness. Removed after 12 months. Expected 10–15% total weight loss.

Swallow Intragastric Balloon

Swallowable capsule balloon — no endoscopy needed for placement. Reduces appetite and supports lifestyle changes with minimal intervention.

Combined with OMM

Adding obesity management medications to any endoscopic procedure improves total weight loss and sustainability — long-term medication compliance is key.

How Medications Work

GLP-1 and GIP-based medications work through multiple mechanisms to support weight loss. They are not a quick fix — medicines need to be taken long term for sustained weight management, and work best when combined with lifestyle changes and clinical monitoring.

Appetite Regulation

GLP-1 agonists act on brain receptors to reduce hunger signals and food cravings throughout the day.

Improved Satiety

Slower gastric emptying creates a prolonged feeling of fullness after smaller meals.

Metabolic Improvement

Improved insulin sensitivity and glucose metabolism — directly benefits diabetes and metabolic syndrome.

Visceral Fat Reduction

Targeted reduction of dangerous visceral fat around organs, lowering cardiovascular disease risk significantly.

Who It's For & Considerations

Medical weight management suits a wide range of patients — from moderate obesity to high-risk surgical candidates. Certain contraindications apply for specific medications that must be evaluated during your initial consultation.

BMI >27.5 with or without co-morbidities
Patients seeking non-surgical weight loss approach
High-risk surgical candidates needing a safer alternative
Bridge therapy before or alongside bariatric surgery

Contraindication: Diabetic retinopathy, history of pancreatitis
Contraindication: Family history of medullary thyroid carcinoma
Risk: Gastric symptoms — acidity, bloating, cramps, reflux
Risk: High failure / weight regain if medications are discontinued

Treatment Pathways

Compare Your Options

OMM Program

Choose the plan that best fits your needs.

GLP-1 / GIP medications (injection or oral)
Personalized diet and exercise planning
Regular metabolic monitoring and follow-up
Expected: 12–16% total weight loss

Enquire Now

Featured

OMM + Endoscopic